DIN 02541416 — OPDUALAG 80 MG; 240 MG
OPDUALAG is a solution of Relatlimab / Nivolumab marketed by BRISTOL-MYERS SQUIBB CANADA. The full Relatlimab / Nivolumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02541416
- Brand name
- OPDUALAG
- Active ingredient
- Relatlimab / Nivolumab
- Strength
- 80 MG; 240 MG
- Dosage form
- SOLUTION
- Route
- INTRAVENOUS
- Manufacturer
- BRISTOL-MYERS SQUIBB CANADA
- Health Canada status
- MARKETED
- Drug class
- PD-1 inhibitor / LAG-3 inhibitor immune checkpoint inhibitor combination (antineoplastic monoclonal antibodies)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.